In 2025, CMAX and Fusion were acquired by New Zealand Clinical Research. By bringing four clinical research companies together under one trans-Tasman organisation, NZCR Group has significantly expanded its breadth of capability across the region. This includes fast regulatory approvals, efficient participant recruitment and access to a diverse population base supported by deep clinical specialisation and expertise.

NZCR Group now has a capacity of more than 150 trial beds and an extensive range of specialisations for both early and later phase trials across New Zealand and Australia, enabling parallel recruitment across a combined population of 30 million people.

This scale strengthens our ability to support large-scale studies as well as complex and rare disease trials where participant numbers are limited. It also creates opportunities for knowledge-sharing, staff exchange and closer collaboration across New Zealand and Australia.

Together, we’re building a more connected, capable clinical research network, delivering better outcomes for sponsors, participants and the wider health ecosystem.